



CERTARA ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG) REPORT

2025

CERTARA[®]

For the year ended December 31, 2024

TABLE OF CONTENTS

PAGE	
3	CEO Letter: Our Commitment to Patients and Progress
5	Certara's Commitment to Sustainability and Corporate Responsibility
6	Health and Social Impact of Our Software and Services
15	Scientific Excellence and Workforce Development
16	Our Core Values
17	Our People and Culture
18	Employee Health and Well Being
21	Community Impact
23	Global Equity and Inclusion
24	Corporate Governance and Compliance
29	Data Privacy and Cybersecurity
33	Building Transparency Through Our Trust Site
34	Quality Products and Services
36	Our Environmental Impact

OUR COMMITMENT TO PATIENTS AND PROGRESS



WILLIAM F. FEEHERY
Chief Executive Officer

At Certara, our mission is to accelerate the delivery of medicines to patients by leveraging advanced biosimulation software, technology, and services. We support critical decision-making across the drug development lifecycle—driving efficiency, enhancing safety and efficacy, and ultimately improving health outcomes for patients worldwide.

With a global team of over 1,500 professionals, we address the most complex challenges in drug development using state-of-the-art technology. Our biosimulation software enables researchers to predict how drugs will behave in diverse populations—including infants, the elderly, and those with co-morbidities—helping to design smarter trials, reduce the number of participants needed, and in some cases, eliminate the need for certain studies, such as drug-drug interaction trials. This not only accelerates timelines and reduces costs but also minimizes the need for testing in animals and humans.

Beyond software, we offer a fully integrated suite of technology-driven services—from early discovery through development, regulatory support, and market access consulting.

Our work spans a broad range of therapeutic areas, including oncology and rare diseases, and encompasses multiple modalities such as small molecules, biologics, and gene therapies. Since 2014, clients using our platforms and services have received 90% of U.S. Food and Drug Administration (FDA) new drug approvals (excluding diagnostics).

We also have a strong track record of strategic acquisitions and successful integration of complementary technologies and capabilities. Since 2013, we've acquired 21 companies—14 of which brought advanced software or technology solutions into our ecosystem. Notable acquisitions include Simcyp, the foundation of our mechanistic biosimulation platform; Pinnacle 21, which strengthens our data management and regulatory capabilities; and Vyasa, which integrates cutting-edge AI across our platform.

In 2024, Certara acquired Chemaxon, a software company that develops leading software products for chemical property prediction, search, and analysis. Used by research scientists globally, Chemaxon software helps to digitize the design, make, test and analyze lifecycle to discover the best new chemical leads.

OUR COMMITMENT TO PATIENTS AND PROGRESS

Certara's Environmental, Social, and Governance (ESG) efforts center around three strategic priorities:

- **Accelerating crucial medicines to patients**

Accelerating medicines is our mission and why we are passionate about coming to work every day. Through our science-and-technology-based approach, we set precedents and expand boundaries in trusted collaboration with our customers. Since 2014, we have worked with nearly 2,400 life sciences companies and academic institutions and have collaborated on more than 8,000 customer projects in the last decade across a variety of therapeutic areas ranging from cancer and hematology to diabetes and hundreds of rare diseases.

- **Advancing scientific thought leadership and knowledge sharing**

Our global team not only powers client success but also drives innovation in the field. Certara professionals regularly publish scientific work, contribute posters and presentations to major conferences, and support education through hundreds of academic software licenses granted worldwide for teaching and research.

- **Increasing engagement with employees**

Our employees are our competitive advantage and create our success. With our growing global team, we have made purposeful efforts to increase engagement with employees and provide support. We are deeply committed to providing opportunities and resources to help our team thrive at Certara.

While we are proud of the progress we have made, we are excited about the road ahead as we continue to further our ESG initiatives.

We believe that there is significant opportunity to continue expanding our positive impact worldwide. We can and must think differently about how we develop medicines, better and faster to improve and help save patient lives worldwide.



CERTARA'S COMMITMENT TO SUSTAINABILITY AND CORPORATE RESPONSIBILITY

Certara is committed to understanding, monitoring, and managing our environmental, social, and economic impact to support sustainable development. Our ongoing commitment to sustainability and corporate responsibility is demonstrated across several **key commitments**:

- Conducting our business in an accountable, honest, and ethical manner
- Being environmentally responsible
- Ensuring a safe and healthy working environment for our employees
- Supporting universal human rights
- Respecting and embracing the global cultures and individual experiences and backgrounds that make up our company community

Our **Board of Directors**, through the **Nominating and Corporate Governance Committee**, holds ultimate oversight of Certara's ESG strategy and is charged with (i) proposing the Company's overarching ESG strategy and (ii) developing, implementing, and monitoring ESG initiatives and policies.

The Company's continued focus is on:

- Health and safety of our employees and the populations we serve, through medical advancement with our services and software
- Corporate integrity and ethical management

- Corporate governance and transparency
- Sustainability promotion
- Environmental impact, and demonstration of targeted progress
- Overseeing communication with employees, investors, and stakeholders on ESG reporting and expectations
- Monitoring developments in ESG and enhancing organizational understanding around our goals and strategies
- Ensuring timely and effective ESG reporting to both internal and external stakeholders

Certara's ESG strategy aligns with globally recognized frameworks, including the **Sustainability Accounting Standards Board (SASB)** standards most relevant to our industry.

Additionally, our GHG inventory follows best practices as defined by the **Greenhouse Gas Protocol** and we will submit an emissions reduction target for validation by the end of the year to the **Science-Based Target Initiative**.

We also support the **UN Global Compact's Ten Principles**, affirming our commitment to ethical, sustainable, and responsible business practices worldwide.

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

\$37.1 M

2024 R&D SPEND
(9% OF REVENUE)

36

NEW SOFTWARE
APPLICATIONS AND
UPGRADES IN 2024

9,000+

CUSTOMER PROJECTS
SUPPORTED IN THE
LAST DECADE

300+

REGULATORY
SUBMISSIONS IN THE
PAST 5 YEARS

Transforming Drug Development Through Biosimulation

Certara's biosimulation solutions play a critical role in modernizing and de-risking drug development. Our platforms are designed to predict both pharmacokinetics (how the body processes a drug) and pharmacodynamics (how a drug affects the body), enabling more informed decisions across all phases of development. By offering both mechanistic and empirical biosimulation approaches, we provide flexible, data-driven support tailored to the therapy's mechanism of action, available data, and specific development goals.

- *Mechanistic biosimulation* models are grounded in scientific principles and biological understanding, often built by domain experts.
- *Empirical biosimulation* leverages statistical modeling and integrates preclinical and clinical data to account for variability in drug response across populations.

Together, these approaches support the design of more efficient clinical trials, reduce complexity and cost, and, in some cases, allow for clinical trial waivers—contributing to faster, safer, and more ethical drug development.

Simcyp™ Simulator: Advancing Regulatory-Grade Mechanistic Modeling

At the heart of our mechanistic modeling platform is the Simcyp Simulator, a trusted solution for physiologically based pharmacokinetic (PBPK) simulation. For over two decades, Simcyp has helped researchers and developers:

- Determine first-in-human dosing
- Optimize clinical study design
- Predict drug-drug interactions (DDIs)
- Set doses for untested or special populations
- Conduct virtual bioequivalence studies
- Evaluate new drug formulations across a range of drug types, including small molecules, biologics, ADCs, and generics
- Set doses for untested or special populations
- Conduct virtual bioequivalence studies
- Evaluate new drug formulations across a range of drug types, including small molecules, biologics, ADCs, and generics

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

Non-Animal Navigator™: Expert Strategy & AI-enabled Biosimulation to Reduce, Refine, or Replace Animal Studies

Our Non-Animal Navigator solution is a perfect example of how Certara is leading the way for a faster, cheaper, more ethical drug development future. For decades, animal testing has been the standard practice in the pharmaceutical industry for evaluating the safety and efficacy of drugs before they enter the clinic. However, animal tests often do not predict drug effects in humans accurately. Additionally, there are ethical concerns associated with animal testing, particularly regarding the use of costly and difficult-to-source non-human primates (NHPs).

Certara has decades of experience using our software and services to help our clients satisfy the 3Rs to reduce, refine, or replace animal studies. However, the impetus for change in the industry has intensified with the FDA's recent announcement to phase out animal testing for monoclonal antibodies (mAbs) and other drugs.

Now, the best-prepared biopharmaceutical companies must 'future-proof' their portfolios to gain a competitive advantage from more predictive evidence generation via AI- and in vitro-based toxicity models, predictive biosimulation, and other new approach methodologies (NAMs).

With thousands of mAbs currently in preclinical development, drug developers face both significant opportunities and shifting regulatory expectations as they move beyond traditional animal studies.

Based on Certara's extensive experience working with the FDA, EMA, and other major health authorities, the Non-Animal Navigator is a flexible solution that offers clients:

- **Strategic Regulatory Guidance** – Design preclinical programs that appropriately incorporate NAMs while ensuring regulatory alignment.
- **Integrated Preclinical Development Planning** – Develop a weight-of-evidence strategy that combines in vitro, in vivo, real-world evidence, and biosimulation data supported by expert toxicology input.
- **Optimized AI-Enabled Modeling Tools** – Accelerate timelines using the industry's most widely adopted platform PBPK platform, the Simcyp Simulator®, along with ready-to-use mAb Quantitative Systems Pharmacology models.

This approach enables clients to advance development faster, reduce costs, and meet growing ethical expectations.

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

Simcyp is continually enhanced with new features and models, and it is widely recognized for producing regulatory-quality results that support global drug approval submissions.

Empirical Biosimulation and the Phoenix™ Platform

Complementing mechanistic modeling, our empirical biosimulation capabilities use pharmacometric modeling to quantify drug efficacy and safety using clinical and preclinical data. This approach is central to Model-Informed Drug Development (MIDD) and helps customers optimize trial design and dosing strategies across diverse patient populations.

Our team of highly experienced pharmacometricians has supported thousands of drug development programs, providing insights that inform regulatory submissions and development milestones.

Our Phoenix™ PK/PD suite is the gold standard in the life sciences industry for analyzing and reporting pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) data. Phoenix features four integrated modules designed to support pharmacometric modeling and streamline workflow, helping organizations manage data and insights with confidence.

Advancing Drug Discovery and In-Silico Development Through Scientific Informatics

In 2024, we expanded our biosimulation capabilities into early-stage drug discovery with the acquisition of **Chemaxon Kft.**, a leading provider of software for chemical property prediction, search, and analysis.

Chemaxon's tools are widely used by research scientists around the world to digitize and streamline the “design–make–test–analyze” cycle essential to discovering high-quality chemical leads.

Certara and Chemaxon have enjoyed a strategic partnership for over a decade, collaborating to deliver integrated solutions that serve the evolving needs of the life sciences industry.

With this acquisition, Certara significantly broadens its reach into drug discovery biosimulation, complementing its robust offerings in later-phase development. This integration provides customers with a more complete end-to-end data and predictive analytics platform, empowering faster, data-driven decision-making from discovery through commercialization.

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

Enhancing Chemical Informatics to Support Smarter Drug Discovery

Certara and Chemaxon offer a suite of complementary technologies that help advance chemical informatics and streamline research workflows across the drug discovery and development process. These tools empower scientists with faster access to meaningful data, facilitate better decision-making, and promote collaboration across research teams and partners.

- **Chemaxon JChem Engines**

A widely adopted chemical search engine that delivers accurate and efficient search results, helping researchers quickly access the information they need to progress scientific programs.

- **Chemaxon Compound Registration**

Supports compound tracking and optimization by enabling comparison of new small molecules against existing libraries—enhancing the speed and structure of lead identification and refinement workflows.

- **Chemaxon Design Hub**

A collaborative design and tracking platform that brings together compound selection, hypothesis development, and computational

tools. Integrated with Certara's D360 solution, Design Hub offers a cohesive experience to support research continuity and productivity.

- **Certara D360™ Software**

A research informatics solution that provides seamless access to integrated data, visualizations, and analytical tools. D360 enables scientific teams to explore Structure Activity Relationships (SAR), prioritize candidates, and manage data-intensive discovery workflows with greater ease and insight.

- **Chemaxon Marvin**

A versatile chemical drawing tool that supports accurate structure representation and real-time validation. Marvin's built-in intelligence enhances research quality by catching errors and supporting predictive calculations.

Together, these offerings reflect a commitment to empowering data-driven science and operational efficiency—key pillars in advancing ethical innovation across the pharmaceutical research landscape.

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

Preclinical and Clinical Data Pipeline & Automation Suite

Certara is committed to supporting innovation and operational excellence across the life sciences ecosystem. Our integrated data solutions are designed to help organizations navigate the increasingly complex landscape of drug development with greater confidence and clarity.

By simplifying data workflows and enhancing process consistency, we enable teams to focus on what matters most—advancing scientific insight and delivering better outcomes. At the heart of our approach is a commitment to continuous improvement, collaboration, and alignment with industry best practices.

Our suite of tools, including the widely adopted Pinnacle 21™ platform, reflects our dedication to quality, adaptability, and supporting the evolving needs of our partners worldwide.

Key solutions include:

- **Pinnacle 21**
A cloud-based platform for clinical data standardization and validation. It ensures datasets conform to regulatory data standards (e.g., CDISC), enabling successful submissions.

We offer two versions:

- ❖ *Enterprise Edition*: Tailored for large-scale pharmaceutical companies with advanced workflow and reporting needs
- ❖ *Community Edition*: A free version for smaller organizations exploring data standardization tools
- **Pinnacle 21 Data Exchange**
Facilitates efficient collaboration between sponsors and external data providers. Users can define and share data standards and metadata specifications, ensuring incoming data adheres to predefined requirements—streamlining integration and improving data consistency.
- **Metadata Repository**
A cloud-based platform that supports faster, standardized study design through controlled terminology and automated generation of Study Data Tabulation Model (SDTM) artifacts. This suite enhances data governance and traceability while improving efficiency.

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

Together, these tools form a digitally enabled data pipeline that reduces development complexity, enhances regulatory readiness, and supports sustainable innovation in drug development.

Regulatory Science and Technology-Enabled Services

Certara provides comprehensive, integrated regulatory science solutions that combine advanced software with deep scientific and regulatory expertise. Our offerings help life sciences companies streamline the development, authoring, and submission of regulatory documentation, accelerating approvals and reducing development timelines.

Regulatory Software Solutions

- **CoAuthor™ – Structured & Assisted Content Authoring with Generative AI**

CoAuthor is an advanced authoring platform designed to simplify the development of regulatory documents and medical communications. It integrates structured content management, cross-functional data sourcing, and generative AI to produce high-quality documents faster and more efficiently. This enables regulatory writers to assemble content confidently while reducing redundancies and errors.

- **GlobalSubmit™ – eCTD Submissions Management Platform**
GlobalSubmit provides a full suite of tools for compiling, validating, publishing, and reviewing electronic Common Technical Document (eCTD) submissions. Trusted by regulatory teams across the globe, it ensures efficient and compliant submissions to global health authorities including the FDA, EMA, PMDA, and others.

Technology-Enabled Regulatory Services

Our expert scientists and consultants use Certara's proprietary software to deliver a wide range of services supporting drug development, regulatory filings, and post-approval activities:

- **Quantitative Systems Pharmacology (QSP)**
QSP combines computational modeling with experimental data to simulate interactions among drugs, biological systems, and diseases. Certara has one of the largest QSP teams in the industry, with expertise spanning immunogenicity, immuno-oncology, and emerging capabilities in neurodegenerative diseases. Our reproducible, regulatory-ready QSP platforms—enhanced by Certara.AI—are being actively shared with U.S., EU, and Japanese regulators to support broader adoption.

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

- **Drug Development and Regulatory Strategy**

We provide strategic guidance and develop comprehensive drug development and regulatory plans. Our experts support decision-making at critical development milestones by integrating biosimulation insights and risk-benefit assessments

- **Pharmacometrics**

Our pharmacometricians apply mathematical and statistical modeling to quantify drug and disease interactions and inform key decisions throughout the development process. These models utilize internal and external preclinical and clinical data to optimize dose, patient selection, and trial design.

- **Data Science and Biometrics**

Certara's data science team supports data analysis, standardization, and transformation. These services are essential for regulatory readiness, enabling faster time to insight and enhancing biosimulation and pharmacometric modeling through robust data pipelines.

- **Clinical Pharmacology**

Our clinical pharmacologists guide early-phase study designs and clinical development strategies across a product's life cycle. Their work integrates biosimulation with regulatory knowledge to optimize study planning and execution.

Regulatory Science

We deliver expert support for a range of submissions—including INDs, NDAs, MAAs—covering CMC, nonclinical, and clinical content. Certara's regulatory writing teams combine deep domain knowledge with advanced authoring tools like CoAuthor to deliver submissions with both quality and efficiency.

Regulatory Operations

Our submission management services include strategic planning, program leadership, submission readiness assessments, document compilation, and eCTD publishing through GlobalSubmit. Certara supports filings to all major health authorities worldwide, ensuring global alignment and operational excellence.

Market Opportunity and the Value of Biosimulation

The markets we serve within the biopharmaceutical industry are large, complex, and continually growing. Traditional drug discovery and development remains a costly, time-intensive, and high-risk endeavor. In 2024, global biopharmaceutical R&D spending was estimated at approximately \$270 billion. Despite these substantial investments, more than 90% of drug candidates fail during development—often after significant time and resource commitments.

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

Certara believes that biosimulation can play a critical role in transforming this paradigm. By applying advanced modeling and simulation technologies, we help our clients increase their probability of success across every phase of drug development.

Research has shown that even modest improvements in success rates—such as a 3% increase at each development stage—can generate cost savings of nearly \$300 million per approved drug.

Moreover, the applications of biosimulation continue to grow. As modeling capabilities evolve, we are constantly identifying new ways to drive value across drug development—from early discovery through regulatory approval—ultimately helping to bring safer, more effective therapies to patients, faster and more cost-effectively.



HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

BPBK modeling used to support label claims

125+ novel drugs used the Simcyp Simulator in lieu of clinical studies

ONCOLOGY

AbbVie	Venclexta (<i>venetoclax</i>)
Agios	Tibsovo (<i>ivosidenib</i>)
Amgen	Blinicyto (<i>blinatumomab</i>)
Amgen	Lumakras (<i>sotorasib</i>)
Ariad	Alunbrig (<i>brigatinib</i>)
Ariad (Takeda)	Iclusig (<i>ponatinib</i>)
AstraZeneca	Calquence (<i>acalabrutinib</i>)
AstraZeneca	Lynparza (<i>olaparib</i>)
AstraZeneca	Tagrisso (<i>osimertinib</i>)
AstraZeneca	Truqap® (<i>capivasertib</i>)
Beligene	Brukinsa (<i>zanubrutinib</i>)
Biohaven	Nurtec (<i>rimegepant</i>)
BluePrint Medicines	Ayvakt (<i>avapritinib</i>)
Celgene	Inrebic (<i>fedratinib hydrochloride</i>)
Daiichi Sankyo	Turalio (<i>peixidartinib</i>)
Daiichi Sankyo	Ezharmia (<i>valmetostat tosilate</i>)
Daiichi Sankyo	Vanflyta® (<i>quizartinib dihydrochloride</i>)
Daiichi Sankyo	Datroway (<i>datopotamab deruxtecan-dink</i>)
Deciphera	Qinlock (<i>ripretinib</i>)
Eisai	Lenvima (<i>lenvatinib</i>)
EMD Serono	Tempmetko (<i>tepotinib hydrochloride</i>)
Genentech	Alecensa (<i>alacatinib</i>)
Genentech	Cotellic (<i>cobimetinib</i>)
Genentech	Gavreto® (<i>pralsetinib</i>)
Genentech	Polivy (<i>polatuzumab vedotin-piia</i>)
Genentech	Rozlytrek (<i>entrectinib</i>)
GSK	Zejula (<i>niraparib</i>)
incyte	Pemazyre (<i>pemigatinib</i>)
Janssen	Balversa (<i>erdafitinib</i>)
Janssen	Lazcluzo (<i>flazertinib</i>)
Janssen	Erlada (<i>apalutamide</i>)
Lilly	Retevmo (<i>selpercatinib</i>)
Lilly	Verzenio (<i>abemaciclib</i>)
Loxo	Jaypirca (<i>pirotrotinib</i>)
Loxo Oncology	Vitravri (<i>larotrectinib</i>)
Menarini/Stemline	Oserdu (<i>elacestrant</i>)
Mirati	Krazati (<i>adagrasib</i>)
Novartis	Farydak (<i>panobinostat</i>)
Novartis	Kisqali (<i>ribociclib succinate</i>)
Novartis	Scemblix (<i>asciminib</i>)
Novartis	Odomzo (<i>sonidegib</i>)
Novartis	Viojoice (<i>alpelisib</i>)
Novartis	Rydapt (<i>midostaurin</i>)
Novartis	Tabrecta (<i>capmatinib</i>)

Oncology continued:

Novartis	Zykadia (<i>ceritinib</i>)
Novartis	Jakavi (<i>roxalotinib</i>)
Nuvation Bio	Ibtrazi (<i>taletrectinib</i>)
Pfizer	Daurismo (<i>glasdegib</i>)
Pfizer	Ibrance® (<i>palbociclib</i>)
Pfizer	Bosulif (<i>bosutinib</i>)
Pfizer	Lorbrena (<i>lorlatinib</i>)
Pharmacyclics	Imbruvica (<i>ibrutinib</i>)
PumaDiabetic	Nerlynx® (<i>neratinib</i>)
Sanofi	Jevtana (<i>cabazitaxel</i>)
Seattle Genetics	Tukysa (<i>tucatinib</i>)
Servier	Voranoig (<i>vorasidenib</i>)
Spectrum	Beleodaq (<i>belinostat</i>)
Spectrum	Ogivveo® (<i>niragacent</i>)
Springworks	Revorfor (<i>revenueb</i>)
Syndax Pharmaceuticals	Ektiviy (<i>mabocertinib</i>)
Takeda	Fruzaqla® (<i>fruquintinib</i>)
Takeda	Lytgobi (<i>futibatinib</i>)
Taiho	Copiktra (<i>duvelisib</i>)
Verastem	

RARE DISEASE

Agios	Pyrukynd (<i>mitapivat</i>)
AkaRx (Eisai)	Doptelet (<i>avatrombopag maleate</i>)
AstraZeneca	Koselugo (<i>selumetinib</i>)
Aurinia	Lupkynis (<i>voclosporin</i>)
Genentech	Enspryng (<i>satralizumab</i>)
Genentech	Evrysdi (<i>risdiplam</i>)
Global Blood Therapeutics	Oxbryta (<i>voxelator</i>)
Intercept	Ocaliva (<i>obeticholic acid</i>)
Ipsen	Sohonus® (<i>palovarotene</i>)
Kadmon	Rezurock (<i>belumosidil</i>)
Merck	Welireg (<i>belzutifan</i>)
Miram	Livmarli (<i>maralixibat</i>)
Mitsubishi Tanabe	Dysval (<i>valbenazine</i>)
Novartis	Isturisa (<i>osilodrostat</i>)
Peloton/Merck	Welireg (<i>belzutifan</i>)
PTC Therapeutics	Emflaza (<i>deflazacort</i>)
Sanofi Genzyme	Cerdelga (<i>eliglustat tartrate</i>)
Soleno Therapeutics	VYKAT™ XR (<i>diazoxide choline</i>)
Sun Pharmaceutical Inc.	Leqselvi (<i>deuruxolitinib</i>)
Traverse	Filspari (<i>sparsentan</i>)
Vertex	Symdeko (<i>tezacaftor/ivacaftor</i>)
Vertex	Trikafta (<i>elixacaftor/ivacaftor/tezacaftor</i>)

CENTRAL NERVOUS SYSTEM

AbbVie	Rinvoq (<i>upadacitinib</i>)
AbbVie	Qulipta (<i>atogepant</i>)
Alkermes	Aristada (<i>aripiprazole lauroxil</i>)
Alkermes	Lybalvi (<i>olanzapine/samidorphan</i>)
Eisai	Dayvigo (<i>lemborexant</i>)
Idorsia	Quvivia (<i>daridorexant</i>)
Janssen	Ponvory (<i>ponesimod</i>)
Kyowa Kirin	Nourianz (<i>istradefylline</i>)
Lilly	Reyvow (<i>lasmiditan succinate</i>)
Novartis	Mayzent (<i>siponimod fumaric acid</i>)
Novartis	Vanrafia (<i>arasantan</i>)
Pfizer	Zavzpret (<i>zavegepant</i>)
UCB	Briviac (<i>brivaracetam</i>)
Vertex	Journavx (<i>suzetrigine</i>)

INFECTIOUS DISEASE

Gilead	Veklury (<i>remdesivir</i>)
GSK	Blujepa (<i>gepotidecin mesylate</i>)
Janssen	Olysio (<i>simeprevir</i>)
Merck	Pifeltro (<i>daravirine</i>)
Merck	Prevymis (<i>letevemovir</i>)
Nabriva	Xenleta (<i>ifefamulin acetate</i>)
Novartis	Egaten (<i>tricalabendazole</i>)
Pfizer	Paxlovid® (<i>nirmatrelvir, ritonavir</i>)
Tibotec	Eduvant (<i>rilpivirine</i>)
Viiv	Cabenuva Kit (<i>cabotegravir/trilpivirine</i>)

GASTROENTEROLOGY

AstraZeneca	Farxigo (<i>dapagliflozin</i>)
AstraZeneca	Movantik (<i>naloxegol</i>)
Helsinn	Akynzeo (<i>fosnetupitant/palonosetron</i>)
Phathom	Voquezna TriplePak (<i>vonoprazan/amoxicillin/clarithromycin</i>)
Shionogi	Symproic (<i>nalmedine</i>)
Shire	Motegrity (<i>prucalopride</i>)

CARDIOVASCULAR

Actelion (J&J)	Ospumit (<i>macitentan</i>)
BMS	Camzyos (<i>mavacamten</i>)
BridgeBio	Attruby (<i>acoramidis</i>)
Johnson & Johnson	Xarelto (<i>rivaroxaban</i>)
Pfizer	Revatio (<i>sildenafil</i>)

ENDOCRINE

AbbVie	Orilissa (<i>elagolix</i>)
Astellas	Veozah® (<i>fezolinetant</i>)
Esperien	Nexetol (<i>bempedoic acid</i>)
Janssen	Invokana (<i>canagliflozin</i>)
Lilly	Olumiant (<i>baricitinib</i>)
Lilly	Mounjaro (<i>tirzepatide</i>)
Merck	Steglatro (<i>ertugliflozin</i>)

OTHER

Galderma	Aklief (<i>trifarotene</i>)
Gilead	Livdelza (<i>seladelpar</i>)
Takeda	Litintency (<i>maribavir</i>)
Vertex	Alyftrek (<i>vanzacaftor, tezacaftor, and deucivacaftor</i>)

Updated July 2025

SCIENTIFIC EXCELLENCE AND WORKFORCE DEVELOPMENT

Empowering the Next Generation of Scientific Leaders

At Certara, scientific excellence is foundational to our mission. Through strategic partnerships, immersive fellowships, and real-world training programs, we are cultivating the next generation of experts in Clinical Pharmacology and Pharmacometrics—disciplines that are essential to accelerating safe and effective drug development.

Developing Talent through Academic Partnerships

Our Drug Development Solutions division actively partners with leading academic institutions to train PharmD, PhD, and post-doctoral students. One of our longest-running collaborations is with the Eshelman School of Pharmacy at the University of North Carolina, where we have sponsored a two-year Fellowship Program since 2020. Participants spend one year in intensive academic training, followed by a second year working alongside Certara's Clinical Pharmacologists on real-world client challenges. To date, seven PharmD fellows have graduated from this program, advancing to careers within Certara, the broader industry, or academia.

Expanding Global Capacity in Pharmacometrics

Certara is committed to increasing access to training in quantitative sciences globally. Through the Certara Applied Pharmacometrics Training Fellowship, we have built one of the most impactful pharmaceutical industry or working directly with Certara pharmacometrics education initiatives in Africa.

In the past three years, over 27 fellows (41% women) have participated in a three-month intensive virtual training program, which includes expert-led coursework and practical assignments. Top performers are selected for additional fellowship placements, where they work directly with Certara pharmacometricians on active projects. Many fellows have co-authored scientific publications and posters for international conferences and are now employed in the pharmaceutical industry or working directly with Certara.

Growing Talent, Creating Opportunity and Promoting Innovation

In the United States, our Quantitative Scientific Solutions (QSS) team recently launched a new academic partnership with the University of Florida, where we teach two graduate-level courses:

- *Introduction to Applied Pharmacokinetics*
- *Pharmacometrics Using Pirana-NONMEM and RsNLME*

These courses are designed to build a robust foundation in applied pharmacology and advanced modeling. In addition, we host PhD and post-doctoral interns in our business units, offering hands-on experience with advanced modeling techniques, tools, and challenges facing modern drug development. These immersive opportunities strengthen the scientific pipeline and support our goal of improving patient outcomes worldwide.

OUR CORE VALUES

We leverage Certara's Core Values in our client proposals and conversations and, importantly, apply these in working together for success.

At Certara, our Core Values of **Challenge**, **Collaborate**, and **Deliver** support us in providing outstanding client service and deliverables and driving an award-winning culture.

By consistently **Challenging** ourselves and each other, we stay on the leading edge of innovation, tackling even the most challenging drug discovery opportunities.

We build unrivaled partnerships and achieve what may, to some, be seemingly impossible by **Collaborating** with our clients and across our global team of software developers, scientists, writers, and leading industry experts. Collaboration also means open communication and trusted support to accelerate medicines and protect and enhance patient lives. And, by **Delivering** on our promises and committing to excellence in everything we do, we support each other and our clients in delivering against our goals.

Our Core Values attract and retain the top talent in our drug development, enabling our clients to achieve superior outcomes while facilitating a positive and empowering work environment.

Certara's Core Values support trusting partnerships that propel the drug discovery industry forward. We are proud of our Core Values and the difference these make in our results and ways of working together.

Our Core Values fuel our success:

- **Fortune Best Workplaces in Biopharma 2022-2024 Great Place to Work 2022-2025**
- **Fortune Best Workplaces in the New York region 2024 (including PA, NJ, and CT)**



OUR PEOPLE AND CULTURE

Engaging and Empowering Our Global Workforce

At Certara, we recognize that fostering a strong culture, living our Core Values, and authentically engaging with our employees are essential drivers of innovation, collaboration, and sustainable growth—especially in a research-based organization.

We regularly conduct our company-wide employee engagement survey to gather direct feedback and assess the employee experience across the business. This survey plays a vital role in identifying strengths and areas for improvement across teams, functions, and geographies. Between global surveys, Certara utilizes pulse surveys to guide targeted improvement initiatives at the business and geographic level while working to maximizing employee support and well-being.

Our leadership uses the insights from this survey to inform concrete,



actionable steps that enhance engagement, drive cultural alignment, and reinforce a shared connection to Certara’s mission of advancing medicine. We view this ongoing feedback loop as critical to ensuring that every Certara employee is supported, empowered, and equipped to build a long-term, meaningful career within the organization.

Certara’s commitment to continuous improvement means we not only listen to employee voices—we act on them. Through follow-up communications, targeted initiatives, and leadership accountability, we are creating a workplace culture that is both inclusive and high-performing.

We believe that when our people thrive, our science advances—and ultimately, patients around the world benefit.



This Great Place To Work® Certification™ recognizes employers with exceptional employee engagement and whose employees have highly favorable views regarding company practices and culture.

Great Place To Work® Certification™ helps companies attract and retain top talent, improve productivity, enhance reputation, and gain valuable insights into their workplace culture.

EMPLOYEE HEALTH AND WELL BEING

A Holistic Approach to Supporting Our People

At Certara, we take a holistic and inclusive approach to employee health and wellbeing, recognizing that a healthy workforce is essential to achieving scientific excellence and long-term business success.

We offer a comprehensive and competitive benefits package that reflects our commitment to supporting the physical, mental, and financial health of our employees globally.

Depending on location, benefits may include pension or retirement savings plans, healthcare coverage, income protection, life insurance, gym membership reimbursements, and generous vacation and sickness leave policies.

In the U.S., Certara offers flexible time off, and in other countries, employees may receive up to 25 vacation days annually, in addition to national holidays.

We also provide financial support for parental leave and assistance for new mothers transitioning back to work. Absences due to illness are proactively managed with empathy and a return-to-work mindset, ensuring that our employees receive the support they need during challenging times.

Certara offers global health and welfare plans tailored to local needs, ensuring all employees receive meaningful and relevant coverage.

Our Global Employee Assistance Program (EAP) provides confidential support on a wide range of topics—from mental health counseling and referrals to life management support. In addition, two members of our team are certified Mental Health First Aiders through the National Council for Mental Wellbeing, enhancing the support available to employees across the company.



EMPLOYEE HEALTH AND WELL BEING

Overview of Employee Benefits

Certara provides a comprehensive and competitive benefits package designed to support the physical, mental, and financial well-being of our global workforce.

Health & Wellness

All full-time employees have access to medical, dental, and vision coverage, along with mental health services and wellness programs. Our EAP provides 24/7 confidential support, and we encourage preventive care through wellness incentives.

- Medical, dental, and vision insurance (global coverage and/or local plans via statutory programs)
- Mental health resources and Employee Assistance Program (EAP)
- Wellness programs (e.g., fitness reimbursement, health screenings)

Work-Life Balance

Certara supports flexible work arrangements including hybrid and remote roles, helping employees balance personal and professional responsibilities.

We offer generous paid time off, and our parental leave policy provides paid leave for all new parents, regardless of gender.

- Flexible working hours
- Hybrid/remote work policy
- Paid time off (PTO), sick leave, parental leave

Financial Security

- Retirement savings plans (e.g., 401(k) with match)
- Bonuses
- Financial wellness tools or education

Learning & Development

- Certara is committed to employee development, offering on-demand learning, leadership training, and tuition assistance. Employees are encouraged to pursue continuous learning aligned with their career goals.
- Training programs
- Tuition reimbursement
- Internal mobility or leadership development programs

We regularly review and tailor our benefits to ensure they are inclusive and responsive to regional needs. In some countries, this may include certain allowances as determined by local market, expanded family leave, or additional health services.

EMPLOYEE HEALTH AND WELL BEING

Championing Health and Engagement in a Hybrid World

At Certara, we recognize that supporting employee wellbeing is essential to sustaining a productive and engaged workforce. Our flexible hybrid work model empowers employees to manage their work and personal responsibilities in ways that foster balance and fulfillment.

To further promote health and connection in this evolving environment, we've introduced a variety of virtual wellness initiatives designed to support both physical and mental wellbeing.

These include:

- Live and on-demand yoga and meditation sessions
- Wellness challenges focused on hydration, movement/ergonomics, fitness, and rest and stress reduction techniques
- Mental health webinars and resources
- A dedicated intranet portal offering wellness tips, lifestyle content, and community engagement opportunities

By nurturing a culture of wellbeing, we aim to create an inclusive and supportive workplace where our teams can thrive—no matter where they're working from.

The Holi Celebration in the Certara India Office was filled with colors, laughter, and festive cheer! From vibrant gulal to delicious sweets, the event brought everyone together, making it a truly memorable occasion.



COMMUNITY IMPACT

Leveraging Our Strengths to Inspire the Next Generation

At Certara, we believe in the power of science to change lives—and we're passionate about sharing that vision with future generations. By engaging with students and supporting STEM education, our employees help build a more inclusive, innovative, and informed scientific community.


Certara employees are deeply committed to giving back to the communities where they live and work, using their unique skills and expertise to make a meaningful impact—especially in the areas of science, education, and career development.

To encourage early interest in science, technology, engineering, and mathematics (STEM), our team participates in the "Letters to a Pre-Scientist" program. This pen-pal initiative connects Certara employees with students in grades 5 through 10 from low-income communities. Through letter-writing exchanges, our scientists and professionals help demystify STEM careers, share their personal experiences, and inspire students to envision their own futures in science and technology.

We also host work experience weeks for local schoolchildren, offering hands-on exposure to careers in drug development, regulatory science, and software engineering.

These immersive opportunities allow students to engage directly with industry professionals and explore real-world applications of classroom learning.

Chemaxon Marketing Team's Kindergarten Breakfast



Certara's Radnor headquarters welcomed 14 curious kids for Bring Your Kid to Work Day! The group enjoyed hands-on science experiments, interactive games, and engaging presentations from team members across the organization.



COMMUNITY IMPACT

Beyond the classroom, Certara employees regularly conduct presentations at local universities, participate in career fairs, and provide guidance to students considering careers in drug development and life sciences. By sharing their knowledge and career journeys, our team members help cultivate a more diverse and prepared pipeline of future scientists and innovators.

These community engagement efforts reflect Certara's broader mission—to accelerate access to safe, effective therapies while strengthening the communities we serve and the future of the global biopharmaceutical workforce.

Team Certara from around the world!



GLOBAL EQUITY AND INCLUSION

Advancing a Culture of Belonging, Fairness, and Respect

Certara's innovative culture is grounded in respect for a wide variety of ideas and perspectives, as well as a deep commitment to the principles of equity and inclusion across our global workforce. We believe that our company values and culture enhance the quality of our science, innovation, and collaboration.

We are committed to fostering a positive, inclusive, and respectful work environment where all employees are treated with dignity and fairness. As part of our onboarding process, every new hire completes unconscious bias training, reinforcing our company-wide expectations for professional and equitable behavior.

To ensure transparency and equal opportunity, promotion opportunities are posted and communicated openly across the company. Pay practices are reviewed regularly to promote fairness and equity across roles, locations, and levels.

Certara supports the continuous development of its people through ongoing technical and soft skills training, career coaching, and a formal performance management process. This helps all employees—regardless of background—grow and advance within the organization.

To strengthen inclusive hiring practices, employees involved in recruitment and selection receive training on nondiscriminatory practices. Additionally, managers involved in the hiring process are also trained periodically on best practices. At Certara, global equity and inclusion are not just policies—they are fundamental values that shape how we grow, how we lead, and how we impact the world around us.

Additionally, each holiday season, Certara hosts a global, worldwide Cultural Celebration, during which various employees share local cultural practices and different ways of celebrating across the globe.



CORPORATE GOVERNANCE AND COMPLIANCE

Board of Directors

Certara's Board of Directors is responsible for overseeing the activities and affairs of the Company as reported by the Chief Executive Officer and the senior management team. The Board plays a critical role in guiding corporate strategy, risk management, and organizational integrity.

Board Oversight of ESG Matters

The Certara Board is committed to ensuring the Company pursues policies and practices that support long-term sustainability and responsible corporate citizenship. Oversight of ESG matters has been delegated to the Nominating and Corporate Governance Committee. They are responsible for developing and implementing Certara's long-term ESG strategy, monitoring performance, and identifying opportunities for continuous improvement.

Director Qualifications and Experience

Certara's directors are selected based on their integrity, judgment, industry knowledge, leadership ability, and relevant experience. In evaluating nominees for the Board, a wide range of factors are considered, including:

- Variety of background and perspectives; experience in corporate governance, finance, accounting, and executive compensation.
- Service on other boards or governing bodies.

- Existing business commitments and potential conflicts of interest.
- Age and tenure, with a policy that directors may serve until their term expires, they resign or are removed by shareholders or reach the retirement age of 75.

We believe this comprehensive approach ensures a Board composition that is well-aligned with the size, scope, and evolving needs of the business.

Board Structure and Leadership

Certara's Board currently consists of ten directors, divided into three classes with staggered three-year terms. Each year, one class of directors stands for election at the annual meeting of stockholders. The Board typically meets five times annually, with additional meetings convened on an ad hoc basis as needed.

The leadership structure of the Board separates the roles of Chief Executive Officer and Chairperson, with Dr. William Feehery serving as CEO and Mr. James Cashman as Chairperson. This separation allows Dr. Feehery to focus on operational execution while Mr. Cashman leads the Board in its oversight and advisory roles.

While the Board does not maintain a rigid policy on the separation of these roles, it believes that flexibility allows it to adapt governance structure based on the evolving needs of the Company. If the Chairperson is not an independent director, the independent directors will appoint a Lead Director to ensure independent oversight is maintained.

CORPORATE GOVERNANCE AND COMPLIANCE

Committees of the Board of Directors

The Certara Board of Directors maintains three standing committees to ensure focused oversight and governance in key areas: the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. These committees play a vital role in assisting the Board with its responsibilities, including risk management, financial oversight, executive compensation, and ESG strategy.

Certara's CEO and other senior executives regularly engage with the non-executive directors and all standing committees to ensure transparent, informed decision-making and effective oversight of the Company's activities.

Compensation Committee

The Compensation Committee assists the Board in fulfilling its responsibilities relating to executive and director compensation, as well as oversight of compensation-related risk. Specifically, the Committee is responsible for:

- Establishing and reviewing executive and director compensation programs, including policies related to pay equity.
- Administering incentive and equity-based compensation plans.

- Approving performance-based goals and evaluating performance relative to those goals.
- Overseeing executive compensation disclosures and preparing the Compensation Committee Report for inclusion in the Company's annual proxy statement.

We believe this comprehensive approach ensures a Board composition that is well-aligned with the size, scope, and evolving needs of the business.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee leads the Board's governance efforts and plays a central role in ESG oversight. Its responsibilities include:

- Overseeing the development and implementation of Certara's ESG strategy and programs.
- Identifying, evaluating, and recommending candidates for Board membership based on pre-established qualifications.
- Reviewing qualifications of current directors for re-nomination and reappointment.
- Recommending director appointments to Board committees.
- Reviewing and recommending updates to Certara's corporate governance policies.

CORPORATE GOVERNANCE AND COMPLIANCE

Audit Committee

The Audit Committee plays a key role in Certara's commitment to strong financial reporting, compliance, and risk oversight. The committee supports the Board in fulfilling its oversight responsibilities and ensures the integrity of the Company's financial statements and internal control framework. Specific responsibilities include:

- Overseeing the quality and integrity of Certara's financial statements, including the accounting and financial reporting processes and audits of financial statements.
- Monitoring internal control systems, including compliance with applicable legal and regulatory requirements.
- Overseeing the qualifications, performance, and independence of Certara's independent registered public accounting firm.
- Administering Certara's corporate compliance program, including the Code of Conduct and anti-corruption policy, and investigating any potential violations.
- Overseeing the Company's risk management policies and practices, including those related to cybersecurity, data privacy, and protection.

- Preparing the Audit Committee Report required by the SEC for inclusion in the Company's annual proxy statement.
- Approving performance-based goals and evaluating performance relative to those goals.

Director Independence

The Board of Directors has determined that all members, except for CEO Dr. William Feehery, qualify as independent under the applicable rules of the SEC and Nasdaq. In addition, the members of the Audit Committee meet the heightened independence standards required for audit committee service. These determinations were made following a thorough review of relevant information, including responses to annual directors' questionnaires.

Corporate Governance Guidelines

Certara's Corporate Governance Guidelines provide a framework for the effective functioning of the Board of Directors and reflect the Company's commitment to strong governance practices. These guidelines cover:

- Board size, composition, and director independence
- Separation of the roles of Chairperson and CEO

CORPORATE GOVERNANCE AND COMPLIANCE

- Conflicts of interest and change in job responsibilities
- Director orientation, education, and performance evaluation
- Succession planning for executive leadership
- Board and committee operations
- Director compensation and stockholder communication
- Implementation of stockholder agreements
- Communication with non-management directors

Additionally, Certara has adopted a Delegation of Authority Policy, which clearly outlines the responsibilities of senior management and distinguishes between routine operational decisions and those requiring Board approval.

Director Stock Ownership Guidelines

To promote long-term alignment between directors and stockholders, Certara has adopted stock ownership requirements for non-employee directors.

Each non-employee director is expected to own Certara common stock equivalent to five times the value of the annual cash retainer (excluding committee retainers) within five years of becoming subject to the policy. This ensures our directors are personally invested in the Company's long-term success and performance.



CORPORATE GOVERNANCE AND COMPLIANCE

Code of Conduct and Ethics

Certara is committed to conducting business with the highest ethical standards and in compliance with all applicable laws and regulations. We have adopted a Code of Conduct that applies to all employees, executive officers, and members of the Board of Directors. This Code provides guidance on a wide range of legal and ethical issues that may arise in the workplace, including:

- Business conduct and integrity
- Conflicts of interest
- Accurate recordkeeping and financial reporting
- Confidentiality and data protection
- Fair competition and antitrust compliance
- Anti-discrimination and anti-harassment
- Health and safety in the workplace

All new employees are required to review and acknowledge the Code of Conduct upon hire, and regular training is provided to reinforce its principles and ensure awareness across the organization.

Employees are encouraged to ask questions, raise concerns, and report any actual or suspected misconduct through multiple reporting channels, including a confidential compliance hotline. Certara maintains a strict non-retaliation policy to protect individuals who make good-faith reports.

Topics that Employees Receive Regular Training On:

Alongside Code of Conduct training, our employees participate in annual training across the following areas:

- Artificial Intelligence (AI)
- Cybersecurity (including Phishing Scams)
- Data Protection
- Global Anti-corruption and Anti-bribery
- Harassment Prevention
- Insider Trading
- IT Security Awareness
- Protecting Personal Data
- Recognizing and Avoiding Social Engineering
- Unconscious Bias

DATA PRIVACY AND CYBERSECURITY

Data Privacy and Security

Certara is committed to protecting the privacy and security of personal information that we collect and use in the course of doing business. We uphold this commitment by complying with all applicable data protection and privacy laws, regulations, and industry standards across the jurisdictions where we operate and provide services.

We have operationalized privacy, security, and compliance to build digital trust across our global operations. This includes establishing a comprehensive Data Security and Privacy Program and governance model that enables us to quickly adapt to evolving regulatory requirements, emerging risks, and changing customer expectations.

Privacy and Security Governance

Certara's Data Security and Privacy Program is led by our Head of Compliance and Data Privacy, who is responsible for the program's overall strategy, design, execution, and reporting. This function sits within the Information Technology organization and has reporting responsibilities to Certara's Executive Leadership Team.

In coordination with the Certara Legal team, the Compliance and Data Privacy function ensures that the company remains in compliance with relevant privacy and security regulations and

frameworks. The Audit Committee of the Board of Directors receives regular updates on the company's data privacy and cybersecurity practices and risk posture.

Program Framework and Practices

Certara's Security and Privacy Program is designed to safeguard information assets against both internal and external threats—whether accidental or intentional. Key features of our program include:

- Use of a third-party privacy, security, and data governance platform to support privacy impact assessments and ongoing risk management.
- A comprehensive data mapping inventory that tracks data flows across systems, vendors, and processes.
- A centralized system to manage and respond to data subject access requests (DSARs).
- Adherence to industry best practices and standards, including:
 - **NIST Risk Management Framework**
 - **NIST Cybersecurity Framework**
 - **NIST Privacy Framework**
- **ISO/IEC 2022 certification** for our Corporate Information Technology and Commercial Software environments.

DATA PRIVACY AND CYBERSECURITY

Personal Data Lifecycle and Privacy Governance

Certara is committed to responsible data stewardship and the protection of personal information throughout its lifecycle. We apply robust controls to govern the collection, creation, use, dissemination, retention, and deletion of personal data to ensure that it is used lawfully, ethically, and only as reasonably necessary for our business operations.

Personal Data Lifecycle Management

We limit the handling of personal data—including sensitive personal information—to that which is legally authorized, relevant, and required for specific business purposes.

Personal data is retained only for as long as necessary to fulfill contractual obligations and comply with applicable laws and regulations.

To safeguard data, we maintain appropriate technical and organizational measures that protect against unauthorized access, unlawful processing, accidental loss, and destruction.

Privacy Choices and Data Subject Rights

Certara respects the privacy rights of individuals in accordance with applicable data protection laws in the jurisdictions where we operate.

We honor individuals' rights to:

- Access their personal data
- Request corrections (accuracy)
- Request deletion (erasure)
- Exercise data portability
- Restrict or object to processing

Individuals may also opt out of certain types of data collection and processing, as permitted by law.

Transparency and Privacy Notices

We maintain transparency with data subjects through clear, accessible privacy notices. These notices describe how and why personal information is collected, used, retained, and shared.

We clearly identify the lawful basis for data processing and actively obtain consent where required. Privacy notices are available on our websites and digital platforms and are updated as needed to reflect regulatory or operational changes.

Online notice here: [Privacy Notice | Certara](#)

DATA PRIVACY AND CYBERSECURITY

Security and Privacy Awareness Training

All Certara employees receive training on privacy and security obligations at the time of onboarding and annually thereafter. Additional, role-specific training is provided to ensure that employees understand and comply with data protection regulations and company policies based on their level of access or responsibility. This reinforces a culture of accountability and compliance.

Privacy by Design and Default

Certara employs a Privacy by Design and Default approach within our project management framework. We proactively incorporate privacy and data protection measures into the design and operation of our systems and processes. We assess privacy risks against the intended use of data and apply controls that are proportionate to the sensitivity and potential impact of unauthorized access or misuse.

Regulatory Obligations and Disclosures

Certara strives to meet all applicable data protection obligations in the jurisdictions where we and our clients operate. In certain cases, we may be required to disclose personal information to governmental or regulatory authorities in compliance with legal requirements. When responding to such requests, we evaluate them carefully to ensure compliance does not infringe on individuals' rights or compromise business integrity.

Third-Party Contractual Obligations

Certara incorporates data privacy and protection obligations into its contracts with clients, contractors, service providers, and third-party vendors. These obligations are defined through data protection agreements and standard contractual clauses that clearly establish the privacy roles, responsibilities, and accountability of each party.

By embedding privacy-by-contract principles into our third-party relationships, we help ensure consistent standards for data protection, regulatory compliance, and risk mitigation across our extended business ecosystem.

Data Security Governance

In most cases when we receive study data from our clients, they are pseudonymized (or key-coded) to mask the participants' identity. Pseudonymization techniques do not exempt Certara from data protection laws, however they do help us meet our data protection obligations.

DATA PRIVACY AND CYBERSECURITY

Information Security and Incident Response

Certara employs advanced cryptographic technologies to safeguard sensitive business data from loss, unauthorized access, or disclosure—whether the data are at rest or in transit. These protections are foundational to maintaining the trust of our clients, partners, and stakeholders.

We maintain a formalized incident response process that guides the identification, assessment, and management of both known and suspected security and privacy-related incidents. This framework ensures timely containment, mitigation, recovery, and documentation of events, as well as clear communication of outcomes to the appropriate stakeholders.

As a result of our robust security posture, Certara has not experienced any reportable data breaches. We have also received no materially adverse audit findings or fines and have responded promptly and effectively to all individual data deletion requests.



BUILDING TRANSPARENCY THROUGH OUR TRUST SITE

Transparency in Action: Launch of Certara's Trust Site

We launched a dedicated Trust Site as part of our ongoing commitment to transparency, accountability, and stakeholder engagement. This digital platform serves as a centralized hub where we openly share information about our ethical practices, data governance, compliance standards, and ESG-related policies. The Trust Site is designed to foster confidence among our partners, customers, and broader community by making our values and actions visible, verifiable, and aligned with global expectations. By creating a space where trust is both built and maintained, we reinforce our belief that long-term success is rooted in integrity, openness, and shared responsibility.

The creation of our Trust Site reflects a strategic investment in transparency and client empowerment. Key benefits include:

- **Enhancing Trust and Confidence** – By providing self-service access to critical compliance and governance information, the Trust Site enables clients to efficiently assess Certara's control environment—minimizing the need for additional questionnaires or audits and streamlining onboarding and due diligence processes.
- **Reinforcing Credibility and Brand Integrity** – The Trust Site demonstrates our proactive approach to transparency and regulatory alignment, strengthening Certara's reputation as a responsible and trustworthy partner in the life sciences ecosystem.
- **Fostering Customer Loyalty** – With regular content updates, subscription options, and easy navigation, the Trust Site (available at trust.certara.com) serves as a dynamic engagement tool that supports long-term customer relationships and repeat interaction.



QUALITY PRODUCTS AND SERVICES

Certara Continuously and Intentionally Fosters a Culture of Quality

At Certara, quality is embedded in every aspect of our operations. We maintain a proactive, risk-based Quality Management System (QMS) that supports sound operational decision-making, regulatory compliance, and the fulfillment of customer quality expectations.

Our electronic Quality Management System (eQMS) is the foundation of Certara's global quality program. It is validated, fully compliant with 21 CFR Part 11, and used across all business units to facilitate harmonized engagement among internal stakeholders.

The eQMS provides a centralized solution for the review and approval of critical quality documents, including policies, standard operating procedures, work instructions, forms, and templates.

As our enterprise-wide training management system, the eQMS also houses training records for Certara processes across the organization. In addition, it serves as the repository for quality events, process deviations, internal and external audit records, and corrective and preventive actions (CAPAs).

The system's robust reporting capabilities allow for real-time and scheduled reporting on key quality metrics—such as training compliance, audit status, and CAPA progress—providing leadership with the insights needed for timely, evidence-based decision-making.

Commitment to Quality and Transparency Through Audits

Certara's dedication to quality and operational excellence is further demonstrated by our robust audit program. Our clients routinely audit our systems and processes to ensure compliance and alignment with their quality standards.

In the past calendar year, Certara successfully completed more than 300 customer audits, many of which were conducted remotely. These audits validate the strength of our quality systems and reflect the transparency and rigor with which we operate. The consistently high success rate is a testament to the effectiveness of our defined processes, internal controls, and our ongoing commitment to ensuring the reliability and integrity of our products and services.



QUALITY PRODUCTS AND SERVICES

Our QMS Principles Include the Following:

- **Social Responsibility.** At Certara, we are committed to cultivating a culture rooted in integrity, quality, and continuous progress. Guided by a strong ethical foundation, we strive to foster accountability and reliability in everything we do—both in how we work and in how we contribute to the broader scientific and global community.
- **Risk Management.** Awareness of and response to identified risks are integrated into Certara's processes to facilitate the continual improvement and provide a structure for consistent quality products and services.
- **Governance.** Certara has implemented an eQMS to provide an industry leading foundation for the management and communication of our interrelated processes that function as a coherent system.
- **Accountability.** Employees receive the required training to comply with company policies, industry standards, and legal guidelines through Certara's eQMS.
- **Internal Stakeholder Engagement.** Facilitate the engagement of people in achieving the organization's quality objectives through our corporate eQMS. A robust training program that enables recognition, empowerment, and enhancement of Certara's workforce.
- **External Stakeholder Engagement.** Commitment to continuous improvement aligning with industry best practices and regulatory guidelines to meet the needs of our clients. Deliver reliable, compliant, and high-quality products and services to our clients and stakeholders.



OUR ENVIRONMENTAL IMPACT

Environmental Commitment

At Certara, we are dedicated to minimizing the environmental impact of our operations. We continually seek to improve our environmental performance and proactively engage in initiatives that preserve and protect the planet.

Our commitment to environmental stewardship and sustainable development is central to how we operate—and extends to our customers, employees, and the communities in which we live and work.

As outlined in our Environmental Policy, we are committed to:

- **Complying** with all applicable environmental, health, and safety laws, regulations, and standards.
- **Preventing pollution** and reducing environmental risks whenever possible.
- **Continually improving** our environmental performance through data-driven measurement and action.
- **Empowering employees** with training and opportunities to actively contribute to our environmental goals.
- **Empowering employees** with training and opportunities to actively contribute to our environmental goals.

- **Implementing effective waste minimization programs**, including reducing, reusing, and recycling materials.
- **Communicating** our environmental priorities and progress transparently with stakeholders.

By embedding sustainability into our business, we aim to deliver long-term value while protecting the environment for future generations.

Office Footprint and Environmental Impact

Certara operates within a limited physical footprint, with office-based facilities and no manufacturing operations. As of year-end 2024, we had 36 offices in 17 countries, and we leased or subleased all of our offices.



We began reducing our office space prior to the COVID-19 pandemic, recognizing that we could operate effectively in a virtual environment. While we continue to value in-person collaboration, we are committed to balancing a reduced office footprint with flexible, hybrid work arrangements.

This approach helps us lower our environmental impact by reducing employee commutes and facility resource usage. We actively monitor office utilization to identify opportunities to further reduce square footage, energy use, and water consumption.

OUR ENVIRONMENTAL IMPACT

Certara's implemented a range of initiatives to support our environmental stewardship goals and reduce our operational impact, including:

- Office-wide paper recycling programs.
- Water filtration systems to eliminate water deliveries.



- Bulk purchasing of office supplies to reduce shipment frequency.
- Reusable kitchenware (stainless steel cutlery, dishes, glasses) to discourage single-use plastics.
- Recyclable coffee pods in all office coffee machines.
- Reuse and donation of furniture when vacating or reconfiguring spaces.
- Default duplex printing to reduce paper use.
- Coordination with building management to align HVAC and energy use with occupancy trends.
- Transition from plastic security badges to electronic access systems.
- Recycling and donation of IT equipment, including laptops, monitors, and peripherals.

In addition, we aim to reduce employee air travel, as part of our broader commitment to minimizing carbon emissions.

OUR ENVIRONMENTAL IMPACT

Sustainable Procurement

At Certara, sustainability is a company value that extends beyond our operations and into our supply chain. We believe that our vendors play a critical role in helping us achieve our environmental, social, and governance goals. To that end, we have adopted a vendor and procurement policy that guides how we evaluate and engage with our suppliers.

As we develop public targets to demonstrate our environmental commitments, we may evaluate various factors when working with vendors, such as:

- **Ethical and Sustainable Practices:** Does the supplier operate responsibly and promote sustainable and ethical practices within their own operations and supply chain?
- **Environmental Stewardship:** Does the supplier have active programs to reduce their environmental impact, including conserving energy, water, and raw materials?
- **Carbon Footprint Reduction:** Can the supplier demonstrate efforts to minimize waste and reduce packaging in support of lower carbon emissions?
- **Local Sourcing:** Does the supplier prioritize local sourcing to reduce the environmental impact of transportation and logistics?

We value partnerships with vendors who share our vision for a more sustainable future and are committed to driving positive change together.



OUR ENVIRONMENTAL IMPACT

Greenhouse Gas (GHG) Emissions – Scope 1, 2, and 3

As part of our ongoing commitment to environmental stewardship and transparent sustainability reporting, we track and disclose our greenhouse gas (GHG) emissions in accordance with the GHG Protocol Corporate Standard. Our emissions inventory encompasses Scope 1, Scope 2, and, where applicable, Scope 3 emissions—ensuring a comprehensive view of our carbon footprint across our operations and value chain

- ❖ **Scope 1 (Direct Emissions):** These emissions arise from sources that are owned or directly controlled by the company. This includes on-site fuel combustion, such as natural gas used for heating, and emissions from company-owned or -leased vehicles. While our Scope 1 emissions remain relatively limited due to the nature of our business, we remain focused on monitoring and minimizing these impacts where possible.
- ❖ **Scope 2 (Indirect Energy Emissions):** Scope 2 accounts for indirect GHG emissions from the generation of purchased electricity, steam, heating, and cooling consumed by the company. These emissions are largely driven by our physical office footprint and HVAC systems. We are actively working to improve energy efficiency in our facilities and explore opportunities to procure cleaner energy where feasible.

- ❖ **Scope 3 (Other Indirect Emissions):** Scope 3 represents all other indirect emissions that occur in our value chain and often comprise the largest share of a company’s total emissions. For us, relevant Scope 3 categories include emissions associated with business travel, employee commuting, purchased goods and services, waste generated in operations, and other upstream and downstream activities. We are working to better understand and quantify these emissions in order to set reduction strategies that align with global climate goals and stakeholder expectations.

We recognize that climate action requires more than measurement—it demands meaningful progress.


As such, we are continually refining our methodologies, enhancing the granularity of our data, and exploring science-aligned emissions reduction targets.

Our ESG program remains anchored in accountability, innovation, and a long-term vision to create a low-carbon, sustainable future.


OUR ENVIRONMENTAL IMPACT

2024 SCOPES 1 -3 INVENTORY

Market-based mtCO2e



Scope 3 mtCO2e



- 1-Purchased Goods & Services ("PG&S")
- 2-Capital Goods
- 3-Fuel- and Energy- Related Activities ("FERA")
- 4-Upstream Transportation & Distribution (T&D)
- 5-Waste Generated
- 6-Business Travel
- 7-Employee Commute
- 13-Downstream Leased Assets

OUR ENVIRONMENTAL IMPACT

2024 Scopes 1-3 Emissions

Scope	Description	2024 GHG Emissions (mt CO2e)
Scope 1	Natural Gas and Refrigerant	160.67
Scope 2 Location-based	Purchased Electricity using regional emission factors	796.48
Scope 2 Market-based	Purchased Electricity using utility-specific emission factors and accounting for Renewables	766.34
Scope 3	All upstream and downstream activities that are applicable to Certara	6,145.99
	Total Location-based Emissions	7,103.14
	Total Market-based Emissions	7,073.00

OUR ENVIRONMENTAL IMPACT

2023-2024 Scopes 1-3 Emissions

Scope	Description	2023 GHG Emissions (mt CO ₂ e)	2024 GHG Emissions (mt CO ₂ e)	YOY % Difference
Scope 1	Natural Gas and Refrigerant	363.34	160.67	-55.78%
Scope 2 Location-Based	Purchased Electricity using regional emission factors	816.41	796.48	-2.44%
Scope 2 Market-Based	Purchased Electricity using utility-specific emission factors and accounting for Renewables	881.58	766.34	-13.07%
Scope 3	All upstream and downstream activities that are applicable to Certara	7,765.85	6,145.99	-20.86%
Total Location-based Emissions		8,945.60	7,103.14	-20.60%
Total Market-based Emissions		9,010.77	7,073.00	-21.51%

OUR ENVIRONMENTAL IMPACT

2023-2024 SCOPE 3 Emissions by Category

1-Purchased Goods & Services (PG&S)	Purchase of products or services. Includes emissions provided by cloud data servers for Certara's software and operations.	5,511.54	3,737.95	-32.18%
2-Capital Goods	Purchases of final products with extended life.	296.76	151.3	-49.02%
3-Fuel- and Energy- Related Activities (FERA)	Extraction, production, transportation of fuels and energy not accounted for in Scope 1 & 2.	355.08	279.88	-21.18%
4-Upstream Transportation & Distribution (T&D)	T&D of products between tier 1 Investments & company; 3rd party transportation & logistics	Not calculated	24.79	N/A
5-Waste Generated	Estimates for disposal and treatment of landfill and recycling waste from Certara facilities.	7.19	6.88	-4.31%
6-Business Travel	Transportation of employees for business. Incl. air, ground, and hotel. Using mileage data or estimated mileage from expense data, assumptions, and research.	770.28	1,513.95	96.55%
7-Employee Commute	Personal commuting of employees between their homes and offices, as well as remote work.	821.31	405.85	-50.59%
8-Upstream Leased Assets	Assets leased from other entities, such as leases/subleases.	3.69	8.38	127.15%
13-Downstream Leased Assets	Assets leased by the company (acting as lessor) to other entities, that are not already included in Scope 1+2 inventory (e.g. machinery, facilities).	Not calculated	17.01	N/A
	Total Scope 3 Emissions	7,765.85	6,145.99	-20.86%



For more information, please visit:

www.certara.com

CERTARA 